Pulike Group Advances Global Pet Health Strategy, Empowers OEM/ODM Services with National R&D Platform

Pulike Group Advances Global Pet Health Strategy, Empowers OEM/ODM Services with National R&D Platform

Pulike Biological Engineering Co., Ltd. (SSE: 603566), a leading animal health enterprise in China, has announced its annual strategic upgrade for the pet health sector. Positioning pet nutrition and care as a core growth segment, the group will leverage its national-level R&D platforms and full-industry-chain production capacity to fully empower the global OEM/ODM services of its subsidiary, Luoyang Meibei Biotechnology Co., Ltd., delivering pharmaceutical-grade custom manufacturing solutions for partners worldwide.

As a benchmark enterprise in China’s veterinary medicine industry, Pulike is the founding host of the National Veterinary Drug Engineering Technology Research Center, and operates three national-level innovation platforms including the National Enterprise Technology Center and the National-Local Joint Engineering Laboratory for Animal Infectious Disease Diagnostic Reagents and Vaccine Development. Its R&D team consists of over 200 experts with master’s and doctoral degrees, with 58 national new veterinary drug registrations and 271 authorized invention patents, boasting profound technical expertise and industrialization experience in veterinary biologics, chemical drugs and deep-processed traditional Chinese medicinenational-v….

Building on over 30 years of technical accumulation in animal pharmaceuticals, Pulike applies human-pharmaceutical-grade R&D and quality control standards to its pet health segment, forming a complete product portfolio covering pet vaccines, chemical medicines and functional health supplements. As the group’s core entity dedicated to custom pet supplement manufacturing, Luoyang Meibei Biotechnology shares the national R&D platform’s technical achievements and GMP-level production management system. It provides full-chain services from formula R&D, dosage form development and compliance filing to mass production and export customs clearance, with products covering more than 10 细分 scenarios including joint care, gastrointestinal regulation, heart support, breeding nutrition and urinary tract health, adapting to regulatory standards and consumer demands across global markets.

In terms of global business expansion, Pulike’s pet segment achieved 15% year-on-year overseas revenue growth in 2025, with products exported to dozens of countries across Europe, North America, the Middle East, North Africa and Latin America. To address export clients’ key needs, Meibei Biotechnology provides complete export documentation including COA reports, Certificates of Origin and Sanitary Certificates, supports compliance with regional standards such as FEDIAF and AAFCO, and offers custom multi-language packaging and technical materials. Its flexible supply chain enables low-MOQ trial orders, fast sample production and mixed container shipping, fully meeting the customized demands of brands, distributors and veterinary channels of all sizes.

A representative from Pulike Group stated that the pet health industry is a core direction of the group’s long-term strategic layout. Going forward, the group will continue to increase R&D investment in the pet sector, accelerate the product application of advanced technologies such as deep-processed Chinese herbal medicine, molecular coating and microencapsulation, and drive the standardized and high-quality development of the pet supplement industry with national-level scientific research strength. The group will also further improve its global OEM/ODM service system, help global pet brands build high-efficacy and highly compliant quality products, and grow the global pet health market together with partners.